Teresita Bello Gonzalez’s Post

#TrendingWithImpact: On March 3, 2024, researchers from Pusan National University published a new research paper in Aging's Volume 16, Issue 5, entitled, “FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.” “This discovery unveils a potential novel molecular target for therapeutic strategies against hepatic steatosis during the aging process [...]” #PressRelease: https://lnkd.in/e4nr7Gyi #aging #hyperlipidemia #steatosis #diet #agingresearch #openaccess #openscience #peerreviewed #journal #publication #publishing #meded

🌟 Advancing Gut Health: Bacillus coagulans BCP92 for Diarrhea Management 🌟 We are excited to share the results of our latest research on the efficacy and safety of Bacillus coagulans (Heyndrickxia coagulans) BCP92 for treating diarrhea. This study marks a significant step in demonstrating the therapeutic potential of probiotics in gastrointestinal health. 🔍 Study Highlights: 1️⃣ Efficacy: Reduced onset and frequency of diarrhea in castor oil-induced animal models. Comparable antidiarrheal efficacy to loperamide at high doses. 2️⃣ Safety: Acute and subacute toxicity studies (up to 2,000 mg/kg) confirmed no adverse effects. No abnormalities in clinical signs, behavior, organ histology, or hematological/biochemical parameters. 3️⃣ Cytoprotective Properties: In vitro MTT assays confirmed no cytotoxicity, establishing BCP92 as a safe probiotic candidate. 💡 What This Means: Our findings position B. coagulans BCP92 as a safe and effective natural intervention for managing diarrhea, further supporting its use as a therapeutic and preventive agent in gut health. 📖 Dive deeper into our findings by reading the full study here: We welcome discussions and collaborations to explore the exciting potential of probiotics in healthcare! #Probiotics #GutHealth #DiarrheaTreatment #ScientificResearch #BacillusCoagulansBCP92 #Innovation

✨#1 Diet Strategy to Manage Irritable Bowel Syndrome ✨ The personalized diet created by Enbiosis AI has clinically demonstrated superiority over the widely recognized low FODMAP diet, long considered the gold standard for managing IBS. Our study titled 'A Multicenter Randomized Controlled Trial Of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low FODMAP Diet' in the prestigious American Journal of Gastroenterology, the leading clinical journal in gastroenterology and hepatology, providing practical and professional support for GI clinicians. Read the full study here: https://lnkd.in/d_6XjSDX #IBS #Gastroenterology #Microbiome #AI #PersonalizedHealthcare #DigestiveHealth #EnbiosisAI #Innovation #Research #HealthcareAdvancement #PersonalizedNutrition

We've published our third study! Our unique microbiome AI-based diet algorithm is the most effective nutritherapeutic solution for IBS patients. And this is just the beginning. We're committed to proving its effectiveness on other diseases, including cancer, because what we've discovered is a revolutionary approach to wellbeing and disease treatment. For investors: We're offering an exceptional valuation/performance investment opportunity. With growing demand, we plan to use the funds to boost our sales, expecting a 5 to 10x return within a year. Enbiosis is the future of biology! #biotechnology #AI #technology #gut #microbiome #IBS #SaaS #B2B #VC

🌟 Exciting News Alert! 🌟 📣 We are thrilled to share that BiOkuris' latest paper, titled "Chitin-glucan improves important pathophysiological features of IBS," has been accepted and published in the esteemed "World Journal of Gastroenterology." 🔍 This groundbreaking study unravels the intricate mechanisms by which Chitin-Glucan (CG) addresses the key pathophysiological aspects of Irritable Bowel Syndrome (IBS), including visceral analgesia, intestinal inflammation, gut barrier function, and toxin chelation. 💊 The findings underscore CG's promise as a novel therapeutic strategy for individuals suffering from IBS or IBS-like symptoms, offering hope for improved management and quality of life. 📚 For the full details of our study, click here ➡️ https://lnkd.in/enmP5jwQ 👏We would like to thank the authors (Caroline Valibouze, Caroline Dubuquoy Bisiaux, Philippe Chavatte, Michaël Génin, Veronique MAQUET, Salvatore Modica Amore, Pierre Desreumaux, Christel Rousseaux) for the high quality and quantity of research that went into this paper and the Service public de Wallonie (Caroline Louis) for their support to fostering innovation. 💪 This milestone represents a significant step forward in our mission to revolutionize gastrointestinal health, and endorses our nomination as a finalist for the most innovative ingredients of the year at Vitafoods Europe. We look forward to continuing our journey towards groundbreaking advancements in the field. Any questions? 📧info@biokuris.com   #IBS #innovation #chitinglucan #gastroenterology

Please register for Hifas da Terra’s next educational webinar ’A Deep Dive into Mycotherapy in Clinical Practice’ Presented by Naturopathic Nutritionist, Tanya Clarke 14th May 2024 - 7:00 PM Do you have a yearning to use mycotherapy with more clients? Are you confused as to how different medicinal mushroom concentrations and formulas can be applied in individual and complex cases? If so, this webinar is for you. Join experienced Mycotherapist Tanya Clarke for an in-depth review of six of her clinical cases. Together we will journey through these detailed case studies and how you might consider applying Hifas da Terra medicinal mushroom formulas for a variety of conditions, ranging from chronic fatigue, eczema, cancer, candida and grief. Through Tanya’s observations you will learn how functional mushrooms and certain strains and combinations can be suitably dosed at different stages of an individual’s quest for health, in order to balance and calm the immune system and ultimately restore emotional equilibrium and vitality. Please click the link to register your spot: https://lnkd.in/epipiZwV

Delving into unmet medical needs in IBS and highlighting our patented technology's ability to address multiple pathways in IBS pathophysiology marks a pivotal stride in our innovation journey. Gratitude to all involved in this research and the creation of this insightful article!

Researchers at the University of Western São Paulo (UNOESTE) and São Paulo State University have uncovered a promising link between curcumin, the primary component of turmeric, and the promotion of beneficial gut bacteria in mice. ---------- For the latest in #healthcare, #medtech, #medicaldevices, #diagnostics and #medical world, follow MedTechAsia.in  ---------- #gutbacteria #curcumin #tumeric #research #researchers #healthcare #medicalmatters #health

Part of my PhD work is out. The study focuses on the effects of the new buffer salt-protected sodium butyrate (NSB) supplementation on the performance, intestinal health, and gut microbiota of broilers. Thank you, my supervisor, and all the teachers! #growthperofrmance #serumanti-inflammatory cytokines, #gutmorphology, #intestinalimmunity #antioxidantcapacity, #SCFA #cecummicrobiota #SKLAN, #IAS #CAAS #Beijing #China https://lnkd.in/gYDwHnia

Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study Effect of Postbiotic Bifidobacterium longum CECT 7347 on Digestive Health Study Overview This study evaluated the impact of heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) on digestive symptoms in healthy adults. It was a randomised, double-blind, placebo-controlled trial with 60 participants over 8 weeks, followed by a check-in at week 10. Key Methods Researchers measured: Gastrointestinal symptoms using various scales Gut microbiome changes Biochemical markers and physical measurements Any adverse effects Main Findings The study found: Small changes in digestive symptoms overall A significant reduction in total and non-HDL cholesterol in the HT-ES1 group An increase in beneficial gut bacteria linked to butyrate production Stable levels of faecal calprotectin in the HT-ES1 group, while it increased in the placebo group Conclusions HT-ES1 may support gut health by: Boosting butyrate-producing bacteria Maintaining normal faecal calprotectin levels Lowering serum cholesterol Clinical Implications Clinical trials are essential for creating safe treatments. To make these benefits accessible, we offer DocSym, an AI-driven platform that integrates clinical standards and research for healthcare professionals. Enhancing Healthcare Delivery Our mobile apps streamline operations by: Facilitating scheduling and treatment monitoring Supporting telemedicine This helps clinics improve patient care and reduce paperwork. Discover more at aidevmd.com. https://lnkd.in/g7d_ZP3j #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics